Celularity Inc. revenue by segment CELU

Annual Quarterly

Celularity Inc. splits its revenue 2 ways in its filings. By operating segments, the largest line in fiscal 2025, which ended Dec 31, 2025 was Degenerative Disease at $17.3 million, 65% of the total. By sales mix, the largest line in fiscal 2025, which ended Dec 31, 2025 was Product at $13.2 million, 50% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019
Revenue	19	27	54	23	18	21	—	—
Operating segments
Degenerative Disease	9 -75.0% share 50.4%	17 -64.2% share 65.2%	48 +179.2% share 89.3%	17 +39.1% share 76.1%	12 -21.2% share 69.3%	16 +81.3% share 74.1%	9	—
Biobanking	5 -11.5% share 24.9%	5 +5.7% share 20.5%	5 -5.5% share 9.5%	5 -1.3% share 23.9%	6 -0.2% share 30.7%	6 -0.6% share 25.9%	6	—
Cell Therapy	5 share 24.7%	4 +453.3% share 14.3%	1 share 1.3%	—	—	—	—	—
Sales mix
Product	7 -72.0% share 35.9%	13 -62.7% share 49.6%	35 +168.7% share 65.2%	13 +250.7% share 57.7%	4 -1.4% share 20.9%	4 -44.5% share 17.8%	7	—
License Royalty And Other	7 -52.5% share 39.2%	8 -42.2% share 29.9%	14 +228.7% share 25.3%	4 -52.0% share 18.4%	9 -27.5% share 48.5%	12 +543.0% share 56.3%	2	—
Services	5 -11.5% share 24.9%	5 +5.7% share 20.5%	5 -5.5% share 9.5%	5 -1.3% share 23.9%	6 -0.2% share 30.7%	6 -0.6% share 25.9%	6	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: CELU (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Florham Park, NJ
SEC filer status: , Emerging growth company
SEC CIK: 1752828
Former names: GX Acquisition Corp. (until Jul 19, 2021)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.